Navigation Links
ACORN CRO Continues Growth in Strong Third Quarter
Date:11/10/2008

ponsor requests for value-driven quality solutions and accelerated patient accruals. With a team approach, ACORN CRO lends itself to highly efficient and accurate trial operations. Close working relationships with community oncology practices enable prompt accruals.

"The trajectory of ACORN CRO for 2009 portends the most successful year for our company," stated Coplon. "We look forward to seeing sponsors at various meetings to showcase our abilities."

For additional information visit http://www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.

ACORN CRO

ACORN CRO is a full-service, oncology-focused contract research organization, providing value-driven, quality solutions to the pharmaceutical and biotech industry and offering unparalleled customer service in monitoring; clinical data management; statistical analysis; medical writing and project management. ACORN CRO delivers insights from key oncology opinion leaders and accelerates the research process through advanced levels of efficiency.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055 x1312

dcoble@sosacorn.com


'/>"/>
SOURCE ACORN CRO
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
2. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
3. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
4. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
5. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
6. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
7. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
8. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
9. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
10. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
11. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... WOBURN, Mass., Nov. 15 BioVex Inc, a ... and,prevention of cancer and infectious disease, announced today it ... of a,venture debt transaction, raising a total of $35m ... to complete its preparations for, and,to commence, a Phase ...
... NASA Goddard Space Flight Center in Greenbelt, Md. proudly ... (CNT) has been named a winner in the third ... category. This award will be celebrated at the Nano ... Briefs National Nano Engineering Conference (NNEC 2007) in Boston, ...
... Nov. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX:,MS), ... sclerosis (MS), today,announced financial and operational results for ... the quarter, we continued to maintain momentum towards ... treatment of multiple,sclerosis," said Kevin Giese, President and ...
Cached Biology Technology:BioVex Closes Second Round of Series E Financing 2NASA Goddard Space Flight Center's carbon nanotube manufacturing technology wins Nano 50 Award 2BioMS Medical announces third quarter 2007 results 2BioMS Medical announces third quarter 2007 results 3BioMS Medical announces third quarter 2007 results 4
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... IRVINE, Calif. , Dec. 2, 2014 /PRNewswire/ ... of globally deployed, innovative test solutions for military, ... the newest version of its successful TS-900 ... the performance and features of high-end systems to ... with outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... crop in states such as Massachusetts, Wisconsin, New Jersey, ... problems for growers trying to realize profits in heavy ... pest damage can have a particularly significant negative impact ... feeding preferences of insects, entomologists have reported that several ...
... , JERUSALEM, ISRAEL, June 22, 2011 Ben-Gurion University ... most comprehensive report to date on Israel,s environmental movement. ... experts and public support, as well as its perilous ... Movement: Trends, Needs and Potential," was presented to Knesset ...
... Evolution is usually thought to be a very ... to adaptive mutations. But environmental change due to things ... very fast. There are just two options for species ... become extinct. So, according to McGill biology professor, ...
Cached Biology News:Pest preferences for cranberry cultivars determined 2Ben-Gurion University team presents environment movement report to Israel's Knesset 2Ben-Gurion University team presents environment movement report to Israel's Knesset 3Evolution to the rescue 2
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
PFM8 Antibody...
Biology Products: